Blood cancer transplant study tests blood pressure drug for immune complication
NCT ID NCT02338232
First seen Apr 09, 2026 · Last updated May 01, 2026 · Updated 4 times
Summary
This study looked at whether the blood pressure drug telmisartan could prevent a serious immune reaction called graft-versus-host disease (GVHD) in people receiving a stem cell transplant for blood cancers. About 32 participants were planned, but the study was stopped early. The main goal was to see how many people developed severe GVHD. This is a disease control study because patients need lifelong monitoring and medication after transplant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GVHD are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
Conditions
Explore the condition pages connected to this study.